Human IgG Fc-engineering for enhanced plasma half-life, mucosal distribution and killing of cancer cells and bacteria
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Monoclonal IgG antibodies constitute the fastest growing class of therapeutics. Thus, there is an intense interest to design more potent antibody formats, where long plasma half-life is a commercially competitive differentiator affecting dosing, frequency of administration and thereby potentially patient compliance. Here, we report on an Fc-engineered variant with three amino acid substitutions Q311R/M428E/N434W (REW), that enhances plasma half-life and mucosal distribution, as well as allows for needle-free delivery across respiratory epithelial barriers in human FcRn transgenic mice. In addition, the Fc-engineered variant improves on-target complement-mediated killing of cancer cells as well as both gram-positive and gram-negative bacteria. Hence, this versatile Fc technology should be broadly applicable in antibody design aiming for long-acting prophylactic or therapeutic interventions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis
Murray, C. J. L., Ikuta, K. S., Sharara, F., Swetschinski, L., Robles Aguilar, G., Gray, A., Han, C., Bisignano, C., Rao, P., Wool, E., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(21)02724-0 · Cited by 16,316 · cited 1×
“RelatedtothisistheglobalconcernforAMRbacteria 61 .”
Reynisson, B., Alvarez, B., Paul, S., Peters, B., & Nielsen, M. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa379 · Cited by 2,361
Neutralizing monoclonal antibodies for treatment of COVID-19
Taylor, P. C., Adams, A. C., Hufford, M. M., de la Torre, I., Winthrop, K., & Gottlieb, R. L. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-021-00542-x · Cited by 732
Schlothauer, T., Herter, S., Koller, C. F., Grau-Richards, S., Steinhart, V., Spick, C., Kubbies, M., Klein, C., Umaña, P., & Mössner, E. (2016) · Protein Engineering Design and Selection · doi:10.1093/protein/gzw040 · Cited by 425 · cited 7×
“By taking advantage of an IgG1 antibody (clone 4497) speci fi c for wall teichoic acid (WTA) on S.aureus 45,46 ,we fi rstshowedthattheWT,REWandPGLALA-containing versions bound equally well to the bacterial surface of an S . aureus strain lacking the two IgG binding molecules SpA and Spi (New-man Δ spA/spi) (Fig.”
InfluentialSelf-citationRobbie, G. J., Criste, R., Dall'Acqua, W. F., Jensen, K., Patel, N. K., Losonsky, G. A., & Griffin, M. P. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01285-13 · Cited by 366
An IgG‐transporting Fc receptor expressed in the syncytiotrophoblast of human placenta
Simister, N. E., Story, C. M., Chen, H., & Hunt, J. S. (1996) · European Journal of Immunology · doi:10.1002/eji.1830260718 · Cited by 332 · cited 1×
“In addition, FcRn mediates transcytosis of IgG across mucosalepithelial barriers and the human placenta 18 – 20 .”
Firan, M., Bawdon, R., Radu, C., Ober, R. J., Eaken, D., Antohe, F., Ghetie, V., & Ward, E. S. (2001) · International Immunology · doi:10.1093/intimm/13.8.993 · Cited by 330
Visualizing the site and dynamics of IgG salvage by the MHC class I-related receptor, FcRn
Ober, R. J., Martinez, C., Vaccaro, C., Zhou, J., & Ward, E. S. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.4.2021 · Cited by 314
Structural Insights into Neonatal Fc Receptor-based Recycling Mechanisms
Oganesyan, V., Damschroder, M. M., Cook, K. E., Li, Q., Gao, C., Wu, H., & Dall'Acqua, W. F. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.537563 · Cited by 259 · cited 2×
“By scrutinizing a human FcRn:IgG1 Fc co-crystal structure 21 , we iden-ti fi ed three Fc amino acid residues that were substituted with the rationale to improve pH-dependent receptor binding, namely Q311R, M428E and N434W (REW) (Fig.”
InfluentialPrabhat, P., Gan, Z., Chao, J., Ram, S., Vaccaro, C., Gibbons, S., Ober, R. J., & Ward, E. S. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0700337104 · Cited by 157
Self-citationMultivalent immune complexes divert FcRn to lysosomes by exclusion from recycling sorting tubules
Weflen, A. W., Baier, N., Tang, Q.-J., Van den Hof, M., Blumberg, R. S., Lencer, W. I., & Massol, R. H. (2013) · Molecular Biology of the Cell · doi:10.1091/mbc.e13-04-0174 · Cited by 101
A human endothelial cell-based recycling assay for screening of FcRn targeted molecules
Grevys, A., Nilsen, J., Sand, K. M. K., Daba, M. B., Øynebråten, I., Bern, M., McAdam, M. B., Foss, S., Schlothauer, T., Michaelsen, T. E., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03061-x · Cited by 98 · cited 3×
“1l),predictive of extended plasma half-life 29 .”
Self-citation
Cited by
Targeting the Neonatal Fc Receptor in Autoimmune Diseases: Pipeline and Progress
Gjølberg, T. T., Mester, S., Calamera, G., Telstad, J. S., Sandlie, I., & Andersen, J. T. (2025) · BioDrugs · doi:10.1007/s40259-025-00708-2 · Cited by 20
Self-citationEngineering intramolecular adjuvants for next-generation vaccines
Wang, Y., Liao, W., Zhang, Z., Wang, T., Zhang, J., Zai, X., & Xu, J. (2026) · The Innovation Medicine · doi:10.59717/j.xinn-med.2026.100258
Lim, S.-K., Lin, W.-C., Pan, Y.-C., Huang, S.-W., Yu, Y.-A., Chang, C.-H., Hu, C.-M. J., Mou, C.-Y., & Mou, K. Y. (2026) · eLife · doi:10.7554/elife.107671.3
Lim, S.-K., Lin, W.-C., Pan, Y.-C., Huang, S.-W., Yu, Y.-A., Chang, C.-H., Hu, C.-M. J., Mou, C.-Y., & Mou, K. Y. (2026) · eLife · doi:10.7554/elife.107671
Metadata
- Authors
- Foss, S., Sakya, S. A., Aguinagalde, L., Lustig, M., Shaughnessy, J., Cruz, A. R., Scheepmaker, L., Mathiesen, L., Ruso-Julve, F., Anthi, A. K., Gjølberg, T. T., Mester, S., Bern, M., Evers, M., Bratlie, D. B., Michaelsen, T. E., Schlothauer, T., Sok, D., Bhattacharya, J., Leusen, J., Valerius, T., Ram, S., Rooijakkers, S. H. M., Sandlie, I., & Andersen, J. T.
- Venue
- Nature Communications
- Published
- 2024-03-07
- Volume
- 15
- Issue
- 1
- Pages
- 2007-2007
- ISSN
- 2041-1723 (ISSN-L)
- OpenAlex
- W4392553115
- Cited by
- 82
- References
- 12
- FWCI
- 18.86
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.